I have also purchased a small holding in this recently. Zoleo appears to be a great product (4-5* on amazon/catch/myer), with ease of use being a key positively reviewed feature. I am interested to see how the government trial is going in the NT as these could be decent recurring contracts if rolled out across all remote emergency services etc.

I am also attracted to the fact that the legacy business is already profitable, and management have skin in the game. I don't like that r&d is capitalised, something to keep an eye on.

The stock appears to be undervalued with the market not pricing in the potential upside from a successful Zoloe rollout.  As someone else mentioned the risk-reward seems to be to the upside at this stage